Anchor
FDA grants final approval to Handa's alternate-salt cancer drug OMCAZIO
Money MovesTaiwan's Handa Pharmaceuticals clears US regulatory hurdles with a laurylsulfate salt of cabozantinib that patients can take with food
Today: Press release confirms OMCAZIO final approvalNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 1 hour agoThe FDA cleared a Taiwanese drugmaker to sell an alternate-salt version of the $2.1 billion cancer drug cabozantinib in the United States. The final approval lands three days after a federal appeals court kept generic entry shut by upholding patents on the originator's salt form.
Handa Pharmaceuticals' OMCAZIO uses the laurylsulfate salt of cabozantinib, approved through Section 505(b)(2), an abbreviated FDA pathway that lets applicants rely on existing safety data plus their own bridging studies. It is bioequivalent to Exelixis's Cabometyx at a roughly 42% lower milligram dose and can be taken with or without food.
The FDA also denied a citizen petition from Exelixis that sought to block approval on safety grounds. Handa now faces the harder test of winning prescriptions in a market Cabometyx has dominated since 2016.
Why it matters
A $2.1 billion cancer franchise now has an FDA-approved rival patients can take with food, built on a salt switch that sidesteps the originator's patents.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
$2.11B
Cabometyx US market sales (2025)
Exelixis's cabozantinib franchise, the market OMCAZIO now enters.
42%
Lower milligram dose for bioequivalence
OMCAZIO reaches equal blood exposure with roughly 42% fewer milligrams than Cabometyx.
3
OMCAZIO capsule strengths
Available as 34.5 mg, 23 mg, and 11.5 mg capsules.
36 days
Tentative to final FDA approval
From July 29, 2026 tentative approval to September 3, 2026 final approval.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Timeline
FDA grants final approval to Handa's alternate-salt cancer drug OMCAZIO
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Loading puzzle…
Tap 💡 Free hint to lock the oldest into slot 1 — that leaves just four to order. Type pills are clues.
0/5
Exact slot
0/5
Within 1
Sign up to save your score and track a streak across stories.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Organizations Involved
HP
Handa Pharmaceuticals, Inc.
Specialty pharmaceutical company (Taiwan Stock Exchange: 6620)
Developer of OMCAZIO
Taiwanese specialty drugmaker that developed OMCAZIO, an alternate-salt formulation of cabozantinib, through its wholly owned US subsidiary Handa Oncology.
HO
Handa Oncology, LLC
US subsidiary
Named applicant for OMCAZIO's US approval
Handa Pharmaceuticals' wholly owned US subsidiary and the named applicant on OMCAZIO's FDA approval.
EI
Exelixis, Inc.
Biopharmaceutical company
Originator of Cabometyx; fought OMCAZIO approval
US biopharma that markets cabozantinib as Cabometyx; holds patents on the drug's malate salt and filed the citizen petition the FDA denied.
U.S. Food and Drug Administration
Federal regulatory agency
Granted final approval to OMCAZIO
The US regulator that granted OMCAZIO final approval and denied Exelixis's citizen petition.
Timeline
November 2025 September 2026
8 events
Latest: Today
Tap a bar to jump to that date
-
Press release confirms OMCAZIO final approval
Today StatementHanda distributes a press release announcing OMCAZIO's FDA final approval and US commercial authorization.
-
Handa discloses approval to Taiwan exchange
StatementHanda files a material disclosure with the Taiwan Stock Exchange confirming the final approval.
-
FDA grants final approval, denies petition
RegulatoryThe FDA converts tentative approval to final, authorizing US commercialization, and denies Exelixis's citizen petition.
-
Federal Circuit upholds malate salt patents
LegalThe appeals court keeps ANDA generic entry on cabozantinib's malate salt closed by upholding Exelixis's patents.
-
Cabozantinib compound patent expires
LegalThe base compound patent covering cabozantinib lapses, removing one barrier to selling a competitive product.
-
FDA grants tentative approval
RegulatoryThe FDA finds OMCAZIO meets quality, safety, and efficacy standards, but patent protection blocks immediate marketing.
-
Exelixis files citizen petition
LegalExelixis urges the FDA to reject Handa's application, arguing the alternate-salt drug raises new safety and effectiveness questions.
-
FDA accepts Handa's OMCAZIO application
RegulatoryThe FDA accepts the 505(b)(2) application for substantive review, setting a July 29, 2026 target action date.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1984
Section 505(b)(2) pathway created (1984)
The 1984 Hatch-Waxman Act created Section 505(b)(2), an abbreviated approval path where applicants can rely on published literature and the reference drug's safety and efficacy data instead of running full clinical trials of their own.
Then
The pathway opened the door to reformulations, new salts, new combinations, and new delivery routes.
Now
It became a standard tool for launching competitive versions of established drugs with far lower development cost and time.
Why this matters now
Handa used exactly this mechanism, bridging to Cabometyx's data while submitting its own bioequivalence studies for the new salt.
2000–2001
Prilosec to Nexium (2000–2001)
As AstraZeneca's blockbuster acid-reflux drug omeprazole (Prilosec) neared US patent expiry, the company launched esomeprazole (Nexium) in 2001. Nexium was the S-enantiomer, a mirror-image version of the same molecule, marketed as a distinct new drug with its own patent protection.
Then
Nexium became one of the best-selling drugs in the world as Prilosec went generic.
Now
The case became the template for product lifecycle management, where chemical variants extend commercial exclusivity beyond an original patent.
Why this matters now
It shows how a chemical modification of an approved drug can reshape market competition, the same logic Handa applied with a different salt form.
2002
Neupogen to Neulasta (2002)
Amgen's daily-injection cancer-support drug Neupogen (filgrastim) spawned pegfilgrastim (Neulasta) in 2002, a chemically modified version requiring one injection per chemotherapy cycle instead of daily shots.
Then
Neulasta extended Amgen's franchise for more than a decade on the strength of fewer injections.
Now
It demonstrated that dosing convenience alone can sustain a modified drug's market leadership.
Why this matters now
A formulation change that improves convenience can dominate an existing market, parallel to OMCAZIO's no-fasting advantage over Cabometyx.
Sources
(7)Related Stories
FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer
New Capabilities
Updated 2 days ago
uniQure files Huntington's gene therapy for FDA and UK approval
New Capabilities
Updated 7 days ago
Zydus buys its way into U.S. specialty drugs
Money Moves
Updated Jun 16
IDEAYA Biosciences raises $324 million as lead cancer drug nears FDA filing
Money Moves
Updated Jun 10
Tarlatamab rewrites treatment for small-cell lung cancer as approvals spread worldwide
New Capabilities
Updated May 31
Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment
Money Moves
Updated May 30